Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG).

被引：0

作者：

Unterhalt, M ^{[1
]}

Hermann, R ^{[1
]}

Koch, P ^{[1
]}

Trumper, L ^{[1
]}

Bodenstein, H ^{[1
]}

Dietzfelbinger, H ^{[1
]}

Landys, K ^{[1
]}

Reuss, M ^{[1
]}

Vetter, H ^{[1
]}

Maschmeyer, G ^{[1
]}

Freund, M ^{[1
]}

Neubauer, A ^{[1
]}

Engert, A ^{[1
]}

Stauder, R ^{[1
]}

Herold, M ^{[1
]}

Tiemann, M ^{[1
]}

Parwaresch, R ^{[1
]}

Stein, H ^{[1
]}

Hiddemann, W ^{[1
]}

机构：

[1] UNIV GOTTINGEN,DEPT HEMATOL ONCOL,D-37075 GOTTINGEN,GERMANY

来源：

BLOOD | 1997年 / 90卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1743 / 1743

页数：1

共 50 条

[31] Bendamustine/mitoxantrone/rituximab (BMR): A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas - Results of a Multicentre phase-II-study of the German low grade lymphoma study group (GLSG).
Weide, R
Koeppler, H
Heymanns, J
Thomalla, J
Hess, G
Gamm, H
Aldaoud, A
Schmitz, S
Haak, U
Plewe, D
Burkhard, O
Gaede, B
Hinrichs, F
Pflueger, KH
Dreyling, M
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 681A - 681A
[32] TREATMENT OF LOW-GRADE NON-HODGKINS-LYMPHOMA BY CYTOREDUCTIVE CHEMOTHERAPY WITH PREDNIMUSTINE MITOXANTRONE FOLLOWED BY INTERFERON-ALPHA-2B MAINTENANCE - RESULTS OF A CLINICAL-PHASE II STUDY
HIDDEMANN, W
UNTERHALT, M
KOCH, P
NAHLER, M
VANDELOO, J
SEMINARS IN ONCOLOGY, 1990, 17 (06) : 20 - 23
[33] FLUDARABINE IN RELAPSED LOW-GRADE NON-HODGKIN LYMPHOMAS - A PHASE-II STUDY OF THE GERMAN LOW-GRADE LYMPHOMA STUDY-GROUP
POTT, C
UNTERHALT, M
SANDFORD, D
MARKERT, H
FREUND, M
ENGERT, A
GASSMANN, W
HOLTKAMP, W
SEUFERT, M
HELLRIEGEL, K
KNAUF, B
NIEBERDING, R
EMMERICH, B
KOCH, P
WORMANN, B
HIDDEMANN, W
BLOOD, 1993, 82 (10) : A575 - A575
[34] Bendamustine/mitoxantrone/rituximab (BMR):: A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas.: Results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide, R
Heymanns, J
Thomalla, J
Köppler, H
Hess, G
Aldaoud, A
Schmitz, S
Unterhalt, M
Dreyling, MH
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 589S - 589S
[35] Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Forstpointner, Roswitha
Unterhalt, Michael
Dreyling, Martin
Boeck, Hans-Peter
Repp, Roland
Wandt, Hannes
Pott, Christiane
Seymour, John F.
Metzner, Bernd
Haenel, Annette
Lehmann, Tanja
Hartmann, Frank
Einsele, Hermann
Hiddemann, Wolfgang
BLOOD, 2006, 108 (13) : 4003 - 4008
[36] Allogeneic stem cell transplantation with dose-reduced conditioning in relapsed follicular and mantle cell lymphoma - A prospective phase II trial of the German low grade lymphoma study group (GLSG)
Dreyling, Martin H.
Beelen, D. -W.
Schleuning, Michael
Ho, Anthony D.
Gramatzki, Martin
Glas, B.
Pfreundschuh, Michael
Wilhelm, Martin
Schmitz, Norbert
Kolb, Hans-Jochem
Unterhalt, Michael
Hiddemann, Wolfgang
BLOOD, 2007, 110 (11) : 899A - 899A
[37] Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Dreyling, MH
Forstpointner, R
Ludwig, WD
Gramatzki, M
Boeck, HP
Haenel, M
Wandt, H
Parwaresch, R
Unterhalt, M
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 567S - 567S
[38] FOLLICULAR LOW-GRADE NON-HODGKINS LYMPHOMA - LONG-TERM OUTCOME WITH OR WITHOUT TUMOR PROGRESSION
ERSBOLL, J
SCHULTZ, HB
PEDERSENBJERGAARD, J
NISSEN, NI
EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 42 (02) : 155 - 163
[39] High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas.: A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
Weide, Rudolf
Hess, Georg
Koeppler, Hubert
Heymanns, Jochen
Thomalla, Joerg
Aldaoud, Ali
Losem, Christoph
Schmitz, Stefan
Haak, Ursula
Huber, Christoph
Unterhalt, Michael
Hiddemann, Wolfgang
Dreyling, Martin
LEUKEMIA & LYMPHOMA, 2007, 48 (07) : 1299 - 1306
[40] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
Lenz, G
Dreyling, M
Hoster, E
Wörmann, B
Dührsen, U
Metzner, B
Eimermacher, H
Neubauer, A
Wandt, H
Steinhauer, H
Martin, S
Heidemann, E
Aldaoud, A
Parwaresch, R
Hasford, J
Unterhalt, M
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1984 - 1992

← 1 2 3 4 5 →